Calgary-based Stem Cell Therapeutics Corp. (SCT) is a biotechnology company focused on the development of its technology platform and intellectual property to selectively induce a patient's own stem cells to proliferate in the brain. SCT's core technology, which includes its lead therapeutic product NTx(TM)-265, has been demonstrated to increase the number of innate adult stem cells that grow in place when this therapeutic approach is applied to test animals. This fundamental technology will be further developed to create specific disease treatments for stroke, Huntington's disease, Alzheimer's disease and other neurodegenerative conditions.
E-mail: info@stemcellthera.com
